Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH) (VOC-PAH)
Volatile Organic Compounds as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension
Sponsor: Maastricht University Medical Center
This observational or N/A phase trial investigates Pulmonary Arterial Hypertension and Systemic Lupus and is currently ongoing. Maastricht University Medical Center leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Sep 2023 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Dec 2021 — Sep 2023 [monthly]
Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Recruiting
▶ Show 4 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Apr 2020 — Nov 2020 [monthly]
Recruiting
-
Feb 2019 — Apr 2020 [monthly]
Recruiting
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Maastricht University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .